Identifying our Research Grant Capacity and Needs

Since 2005, the Childhood Cancer Canada Foundation has supported C17 Council’s research grants program. Each year, the funds have been used to support scientifically sound, peer-reviewed grants awarded by our C17 Research Network. Our partners are increasing, our capacity in Canada to conduct research is growing, and last year we handed out just under $1 million in our research and education grants program. A huge leap from the two $41,000.00 and $17,000.00 grants we awarded in the first grant competition in 2005. Last year we were recognized in the CCRA publication Cancer Research Investment in Canada, 2005-2009 for an incredible 1869% increase in the grant funding we have disbursed.

Having built capacity in the research community across Canada however, means that we continue to work towards increasing the number of research grants we can fund, developing the capacity to fund larger, longer-term, more ambitious research studies and work to train and fund new researchers in pediatric hematology and oncology.

Our current research operating grant competition had a record 24 Letters of Intent submitted in November 2012, with a total budget request of $3.7 million, if we had the capacity to fund them all. We hope that our record of success will continue as we work to improve outcomes and improve the quality of life for all our survivors. Thank you for all the support you have given our research program, we hope we can look forward to our partnership continuing to help improve outcomes and a better quality of survivorship for every child in Canada.

C17 strives to improve health outcomes and quality of life for children and adolescents in Canada with cancer and blood disorders, and to eliminate disparities in care and outcomes wherever they occur.
1. Targeting Polo-Like Kinases (PLK) in Refractory Pediatric Leukemia, Neuroblastoma, Brain Tumours: In Vitro Cytotoxicity, Drug Synergy And Target Modulation Of The Novel Inhibitor BI-6727
Dr. Aru Narendran, Alberta Children’s Hospital
Dr. Sylvain Baruchel, Sick Kids Hospital
Dr. Sandra Dunn, BC Children’s Hospital

2. IND.203, SB939: Refractory solid tumors & leukemia Partnership with NCIC CTG

3. Pharmacogenetic analysis of cyclophosphamide metabolism in pediatric acute lymphoblastic leukemia patients. Dr. Richard Kim, London Health Sciences Centre

4. In vivo anti-tumor and anti-metastatic activity and functional imaging of palifosfamide in preclinical neuroblastoma models. Dr. Sylvain Baruchel, Sick Kids Hospital

---

Overview of DVL Funded Grants

1. Targeting Polo-Like Kinases (PLK) In Refractory Pediatric Leukemia, Neuroblastoma, Brain Tumours: In Vitro Cytotoxicity, Drug Synergy And Target Modulation Of The Novel Inhibitor BI-6727
Dr. Aru Narendran, Alberta Children’s Hospital
Dr. Sylvain Baruchel, Sick Kids Hospital
Dr. Sandra Dunn, BC Children’s Hospital

2. IND.203, SB939: Refractory solid tumors & leukemia Partnership with NCIC CTG

3. Pharmacogenetic analysis of cyclophosphamide metabolism in pediatric acute lymphoblastic leukemia patients. Dr. Richard Kim, London Health Sciences Centre

4. In vivo anti-tumor and anti-metastatic activity and functional imaging of palifosfamide in preclinical neuroblastoma models. Dr. Sylvain Baruchel, Sick Kids Hospital

---

Research Network Grants Awarded

<table>
<thead>
<tr>
<th>Year</th>
<th>Grants Submitted</th>
<th>Funded: Grants</th>
</tr>
</thead>
<tbody>
<tr>
<td>2005</td>
<td>$100,000</td>
<td>$154,800</td>
</tr>
<tr>
<td>2006</td>
<td>$419,455</td>
<td>$424,769</td>
</tr>
<tr>
<td>2007</td>
<td>$315,478</td>
<td>$518,237</td>
</tr>
<tr>
<td>2008</td>
<td>$255,384</td>
<td>$755,384</td>
</tr>
<tr>
<td>2009</td>
<td>$700,000</td>
<td></td>
</tr>
</tbody>
</table>

---

Round 14 – June 2012 Research Grants

24. Bone Marrow failure-causing alleles in Canada and genotype phenotype correlation
Dr. Yigal Dror, Sick Kids Hospital

25. Generation and Validation of the Self PBQ Parent, provider, and survivor perspectives of investigational fertility preservation interventions for pre-pubertal boys with cancer: Exploring the factors influencing decisions and measuring preferences
Dr. Armando Lorenzo, McMaster University

26. Elucidation of YB-1 as a metastatic driver through angiogenic mechanisms in Ewing family tumours using zebrafish and mouse models
Dr. Jason Berman and Dr. Poul Sorenson, IWK Health and BC Children’s Hospital

---

C17 Granting Requests and Funding Summary

C17 Council
3-5908 Edmonton Clinic Health Academy
11405-87 Avenue
Edmonton, Alberta T6G 1C9

Kathy Brodeur-Robb
Executive Director
Phone 780.248.5590
Fax 780.492.8304

Find us on the Web:
www.c17.ca